Akero Therapeutics Inc Cash Flow Conversion Efficiency
Akero Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Akero Therapeutics Inc (AKRO) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.17 Million) by net assets ($957.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Akero Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of Akero Therapeutics Inc from 2017 to 2024. This chart illustrates how Akero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Akero Therapeutics Inc stock price today for real-time trading data and today's change.
Akero Therapeutics Inc Cash Flow Conversion Ratio Explained
Akero Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Akero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akero Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Akero Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Airways International Public Company Limited
BK:THAI
|
0.005x |
|
Loncin Motor Co Ltd
SHG:603766
|
0.084x |
|
Energy Fuels Inc
NYSE MKT:UUUU
|
0.011x |
|
PTT GLBL CHEM.-NVDR- BA10
F:GCB1
|
-0.057x |
|
Grupo Elektra S.A.B. de C.V
MX:ELEKTRA
|
0.144x |
|
Hangzhou Great Star Industrial Co Ltd
SHE:002444
|
0.030x |
|
Liberty Broadband Srs C
NASDAQ:LBRDK
|
-0.012x |
|
Hangzhou First PV Material Co Ltd
SHG:603806
|
0.057x |
Annual Cash Flow Conversion Efficiency for Akero Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Akero Therapeutics Inc from 2017 to 2024. Review financial agility of Akero Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $750.11 Million | $-230.11 Million | -0.307x | -12.96% |
| 2023-12-31 | $535.31 Million | $-145.37 Million | -0.272x | +4.15% |
| 2022-12-31 | $326.56 Million | $-92.52 Million | -0.283x | +39.87% |
| 2021-12-31 | $169.11 Million | $-79.68 Million | -0.471x | -72.17% |
| 2020-12-31 | $258.71 Million | $-70.80 Million | -0.274x | +1.12% |
| 2019-12-31 | $128.73 Million | $-35.63 Million | -0.277x | -398.72% |
| 2018-12-31 | $-49.92 Million | $-4.62 Million | 0.093x | -90.35% |
| 2017-12-31 | $-4.56 Million | $-4.38 Million | 0.960x | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more